Prominence of bioresponsive DNA nanococoons in tackling post-surgery cancer recurrence.
Sravani YerramRamesh JogaPooja ShendePriya VarpeKiran Kumar BellapuSandeep KumarPublished in: Pharmaceutical patent analyst (2023)
Post-surgery cancer recurrence is one of the reasons for increased cancer cases. The effective usage of the enhanced permeability and retention effect of a nanocarrier infused with the bioresponsive release mechanism of checkpoint inhibitors (aPD1 and aCTLA4) can become a boon to mankind. DNA nanococoons (DNCs) comprising Cytosine-phosphorothioate-Guanine oligodeoxynucleotides (CpG-ODNs) with potent immunostimulatory effects can significantly enhance anti-cancer activity. Triglycerylmonostearate (TGMS) with enzymatic cleavage potential at the wound sites of tumor resection, upon caging with restriction enzyme (HhaI) followed by attaching to DNCs, makes the immunotherapy bioresponsive. Hhal-TGMS-DNCs-aPD1 triggered by the inflammation at the wound site undergoes enzymatic cleavage, releases the restriction enzyme, converts DNCs to CpG ODNs sequentially and with sustained aPD1 release exerts an appreciable anti-cancer effect.
Keyphrases
- papillary thyroid
- minimally invasive
- squamous cell
- surgical site infection
- dna methylation
- oxidative stress
- drug delivery
- coronary artery bypass
- dna damage
- cell free
- gene expression
- single molecule
- dna binding
- coronary artery disease
- nitric oxide
- squamous cell carcinoma
- childhood cancer
- cell cycle
- climate change
- anti inflammatory
- acute coronary syndrome
- human health